Below are some of the significant cases in which our firm is involved. You can read more about any underlined case by following that link.
November 14, 2012
If you took GranuFlo and Naturalyte and underwent hemodialysis and suffered any serious adverse health
effects, please call (877) 800-1450 to speak to Finkelstein
Thompson LLP attorneys who are available to analyze your situation at no cost or
obligation to you. If you do not know if Granuflo was used for your
hemodialysis treatment, Finkelstein Thompson LLP can even help you learn
GranuFlo and Naturalyte are used to treat acute and chronic
renal (kidney) failure during hemodialysis. The Food and Drug
Administration ("FDA") recalled
the drugs after they were linked to serious adverse health effects. These drugs were part of a Class I recall which are the most serious type of recall issued by the FDA. Class I recalls involve situations in which there is a reasonable probability
that use of the recalled products will cause serious adverse health
consequences or death. Indeed, as a result of the formulation of
Naturalyte and GranuFlo, it is believed patients were at a higher risk
of heart and cardiovascular injuries, including cardiac arrest, heart
attacks, congestive heart failure, and death.
November 12, 2012
Finkelstein Thompson LLP is investigating allegations that Medtronic,
Inc. illegally promoted and attempted to conceal the adverse events
associated with InFUSE® Bone Graft ("InFUSE"), Medtronic, Inc.'s
bio-engineered bone graft device used for spinal surgery. It is alleged
that Medtronic, Inc. illegally promoted the off-label use of InFUSE for
posterior lumbar surgery, when InFUSE is FDA-approved for anterior or
abdominal lumbar surgery. It is also alleged that Medtronic, Inc.
intentionally minimized or downplayed the risks of serious side effects
related to the use of InFUSE, including ectopic or uncontrolled bone
growth, inflammatory reactions, back and leg pain events, urinary
retention, retrograde ejaculation, and implant displacement.
If you experienced complications from the use of InFUSE and wish to
discuss your rights or provide information to assist the investigation,
Finkelstein Thompson LLP welcomes your call. Finkelstein
Thompson's Washington, D.C. office can be reached at (877)337-1050, or
by email at
November 12, 2012
Thompson LLP ("FT") is investigating patient claims as a result of receiving
potentially contaminated steroid injections into the spinal area. FT is
also investigating claims of fungal infections from steroid injections into
peripheral joint spaces, such as knees, shoulders, or ankles.
to the CDC, healthcare facilities in twenty-three states were shipped lots of
the contaminated steroids. A list of those facilities can be found at the
The infected patients identified as of October 14, 2012, had all received the
preservative-free (PF) methylprednisolone acetate (80mg/ml) injection from the
three lots voluntarily recalled by the New England Compounding Center in
Framingham, Massachusetts, on September 26, 2012.
If you believe you may have received one of the contaminated steroid injections
and wish to discuss your rights or provide information to assist the
investigation, Finkelstein Thompson LLP welcomes your call. Finkelstein
Thompson's Washington, D.C. office can be reached at (877)337-1050, or by email